High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

• Status: RECRUITING
• Trial end date: 2026-09-01

Summary

This is a prospective, randomised, uncontrolled phase II clinical trial planned to include 84 subjects with metastatic lung adenocarcinoma that had progressed after first- or second-line treatment with Osmertinib, who were randomly assigned to trial group 1 and trial group 2, and were given Furmonertinib 160 mg and 240 mg once/day, orally, respectively, with efficacy evaluated every 6 weeks until disease progression, intolerable toxic side effects, or Subjects voluntarily withdrew informed consent.

• Phase: PHASE2

Details

• Lead Sponsor: Changhai Hospital
• Collaborators: Fujian Provincial Hospital; Second Affiliated Hospital of Wannan Medical College; Shanghai Changzheng Hospital; Shanghai Chest Hospital; The First Affiliated Hospital of Bengbu Medical University; The First People's Hospital of Changzhou; The General Hospital of Eastern Theater Command
• Treatments: aflutinib